Avacta Group PLC – AVCT – AffiDX Receives CE Mark for Consumer Self-Testing
Avacta Group plc (AIM: AVCT) announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU…
Avacta Group plc (AIM: AVCT) announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU…
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the main phase of its 200 patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.
ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on its therapeutic drugs, VAL201 and its current clinical status.
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology currently focused on sexual health and pain, is pleased to announce the completion of patient recruitment for the first European Phase 3 study, “FM57”, of MED2005.
Polarean Imaging plc (AIM: POLX), the clinical stage medical-imaging technology company, with a proprietary drug-device combination product for the visualisation of pulmonary function in the magnetic resonance imaging (MRI) market, announces a further update regarding the Company’s Phase III Clinical Trials, following the Company’s announcement of 13 May 2019.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that it has selected the clinical development candidate for first-time-in-human clinical trials of the Affimer platform.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the first phase of its ovarian cancer clinical verification study has reported positive results.
Positive Top Line Results for Early Cancer Detection Test – Lung Cancer Scotland Study.
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce positive results from its Parsortix FDA clinical study for metastatic breast cancer.
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of Live Biotherapeutics, today announced that data from the completed Phase Ib clinical study of Thetanix® for the treatment of Crohn’s disease will be presented on 18 May in a poster session at the 2019 Digestive Disease Week meeting in San Diego.